Uploaded image for project: 'eCQM Issue Tracker'
  1. eCQM Issue Tracker
  2. CQM-6323

CMS 347 - Statin allergy developed during the measurement period.

XMLWordPrintable

    • Icon: EC eCQMs - Eligible Clinicians EC eCQMs - Eligible Clinicians
    • Resolution: Answered
    • Icon: Moderate Moderate
    • None
    • None
    • Hide
      Thank you for your inquiry specific to CMS347v6: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease. The patient would meet the numerator criteria defined as patients who are actively using or who receive an order (prescription) for statin therapy at any time during the measurement period and therefore not be excluded. If this patient had not been prescribed a statin, they would qualify for a denominator exception due to their statin allergy.

      Show
      Thank you for your inquiry specific to CMS347v6: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease. The patient would meet the numerator criteria defined as patients who are actively using or who receive an order (prescription) for statin therapy at any time during the measurement period and therefore not be excluded. If this patient had not been prescribed a statin, they would qualify for a denominator exception due to their statin allergy.
    • CMS0347v6

      Hello,

      We have a patient who is showing as meeting the numerator for CMS 347 Statin therapy for prevention CVD.  The patient was given a statin in May 2023 but did not tolerate it and the physician added an allergy to statins in July 2023. 

      Since this patient was temporarily on a statin med, but then had the statin allergy listed, does the patient meet the numerator or should they be excluded?

      Thank you in advance.

            edave Mathematica EC eCQM Team
            olson.peggy2@mayo.edu Peggy Olson (Inactive)
            Votes:
            0 Vote for this issue
            Watchers:
            3 Start watching this issue

              Created:
              Updated:
              Resolved:
              Solution Posted On: